Compare Amylx Pharmaceuticals Inc (AMLX) vs LTC Properties Inc (LTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs LTC Properties Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while LTC Properties Inc trades at $39.94 (market cap $1.99B). The key difference: Amylx Pharmaceuticals Inc and LTC Properties Inc are close in size by market cap, and LTC Properties Inc pays a 5.87% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LTC | |
|---|---|---|
Market Cap | $1.98B | $1.99B |
Sector | Health | Real Estate |
52-Week High | $18.70 | $40.36 |
52-Week Low | $7.64 | $33.98 |
Enterprise Value | $1.70B | $2.84B |
Dividend Yield | — | 5.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
LTC Properties trades at $38.86, down 0.72% on the day, with a bullish technical signal from moving averages and a neutral RSI. The REIT shows strong profitability with a 39.09% net income margin and a P/E of 15.24. Recent acquisitions, including a $73 million SHOP portfolio expansion (Business Wire, 2026-07-08), highlight growth initiatives, while consistent monthly dividends of $0.19 provide income appeal.
The outlook is mixed: analyst consensus leans Hold (59.09%) amid recent earnings misses, but bullish technicals and strategic shifts to seniors housing offer upside. Risks include execution on SHOP transitions and debt levels, with net cash flow turning negative in 2026. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
